Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

[1]  M. Ellis,et al.  Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial , 2016, The Lancet.

[2]  M. Ellis,et al.  Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Didier Verhoeven,et al.  Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial , 2013, Journal of the National Cancer Institute.

[5]  J. Forbes,et al.  The sequential use of endocrine treatment for advanced breast cancer: where are we? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Nicholson,et al.  Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study , 2012, Breast Cancer Research and Treatment.

[7]  A. Howell,et al.  Fulvestrant revisited: efficacy and safety of the 500-mg dose. , 2011, Clinical breast cancer.

[8]  L. Vahdat,et al.  Treatment of metastatic breast cancer: second line and beyond. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[10]  H. Iwata,et al.  Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Neven,et al.  Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) , 2010, Breast Cancer Research and Treatment.

[13]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Robertson,et al.  Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. , 2003, European journal of cancer.

[15]  M. Dowsett,et al.  Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer , 2001 .

[16]  P. Lønning,et al.  Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Wakeling,et al.  Similarities and distinctions in the mode of action of different classes of antioestrogens. , 2000, Endocrine-related cancer.

[18]  G. Hortobagyi,et al.  Treatment of breast cancer. , 1998, The New England journal of medicine.

[19]  Nicholas E. Roberti,et al.  The role of histologic grading in the prognosis of patients with carcinoma of the breast , 1997, Cancer.

[20]  Eld,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.

[21]  Cynthia X. Ma,et al.  Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT , 2009 .

[22]  V. Kataja,et al.  Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Dowsett,et al.  Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. , 2001, Cancer research.